
    
      This study is a double-blind, placebo controlled study with three phases;

        1. a pre-study medication washout/screening phase upto 3 weeks

        2. a 3-week, open label phase

        3. a 6-week double-blind phase At the end of 3-week in the open label phase, subjects may
           enter the double-blind phase if they meet the eligibility criteria.

      Eligible subjects will be randomized in a blinded fashion either to continue with SKL11197 at
      300 mg TID or to take the same number of placebo capsules.
    
  